PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
Immune checkpoint inhibitors (ICIs) induce T-cell activation against cancer cells, and due to their anti-tumor function in multiple cancers, ICIs have been considered an important option for oncotherapy. PD-1/PD-L1 inhibitors are now widely used as ICIs for many types of cancers in clinical practice...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.835510/full |
| _version_ | 1811300444770664448 |
|---|---|
| author | Hao Dong Yihang Qi Xiangyi Kong Zhongzhao Wang Yi Fang Jing Wang |
| author_facet | Hao Dong Yihang Qi Xiangyi Kong Zhongzhao Wang Yi Fang Jing Wang |
| author_sort | Hao Dong |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) induce T-cell activation against cancer cells, and due to their anti-tumor function in multiple cancers, ICIs have been considered an important option for oncotherapy. PD-1/PD-L1 inhibitors are now widely used as ICIs for many types of cancers in clinical practices. Myocarditis induced by anti-PD-1/PD-L1 agents is uncommon but shows potentially fatal toxicity. In this review, we attempted to conclude the incidence, characteristics, diagnosis, and treatments, as well as illustrate the potential pathogenesis from the perspectives of T-lymphocyte infiltration, disturbance of regulatory T cells, cytokines, macrophage-mediated inflammatory response, and synergistic effect of PD-1/PD-L1 and CTLA4. |
| first_indexed | 2024-04-13T06:51:17Z |
| format | Article |
| id | doaj.art-649d6d8a5555439ea53a4a1d63a331de |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T06:51:17Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-649d6d8a5555439ea53a4a1d63a331de2022-12-22T02:57:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-04-011310.3389/fphar.2022.835510835510PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential MechanismHao DongYihang QiXiangyi KongZhongzhao WangYi FangJing WangImmune checkpoint inhibitors (ICIs) induce T-cell activation against cancer cells, and due to their anti-tumor function in multiple cancers, ICIs have been considered an important option for oncotherapy. PD-1/PD-L1 inhibitors are now widely used as ICIs for many types of cancers in clinical practices. Myocarditis induced by anti-PD-1/PD-L1 agents is uncommon but shows potentially fatal toxicity. In this review, we attempted to conclude the incidence, characteristics, diagnosis, and treatments, as well as illustrate the potential pathogenesis from the perspectives of T-lymphocyte infiltration, disturbance of regulatory T cells, cytokines, macrophage-mediated inflammatory response, and synergistic effect of PD-1/PD-L1 and CTLA4.https://www.frontiersin.org/articles/10.3389/fphar.2022.835510/fullimmunotherapymyocarditisepidemiologymechanismPD-1/PD-L1 inhibitors |
| spellingShingle | Hao Dong Yihang Qi Xiangyi Kong Zhongzhao Wang Yi Fang Jing Wang PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism Frontiers in Pharmacology immunotherapy myocarditis epidemiology mechanism PD-1/PD-L1 inhibitors |
| title | PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism |
| title_full | PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism |
| title_fullStr | PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism |
| title_full_unstemmed | PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism |
| title_short | PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism |
| title_sort | pd 1 pd l1 inhibitor associated myocarditis epidemiology characteristics diagnosis treatment and potential mechanism |
| topic | immunotherapy myocarditis epidemiology mechanism PD-1/PD-L1 inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.835510/full |
| work_keys_str_mv | AT haodong pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism AT yihangqi pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism AT xiangyikong pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism AT zhongzhaowang pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism AT yifang pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism AT jingwang pd1pdl1inhibitorassociatedmyocarditisepidemiologycharacteristicsdiagnosistreatmentandpotentialmechanism |